anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Particulate embolotherapeutic compositions are described in which the particles comprise a matrix polymer expressing at surfaces available for interaction with biological molecules or, usually, blood cells, express zwitterionic groups, usually phosphoryl choline groups. The particles have suitable size and compressibility, for instance controlled by controlling the water content, for use in embolotherapy, by administration using catheters or hypodermic needles. The matrix polymer may be crosslinked. Preferably the particles are spherical. Examples are crosslinked polyvinylalcohol matrices coated with a crosslinkable copolymer formed of 2-methacryloyloxyethyl-2'-trimethylammoniumethyl phosphate inner salt with nonionic and crosslinkable comonomers. The coating is stabilised by crosslinking after coating from an organic solvent solution.
Participants performed exercises daily at home for 6 weeks without wearing the BALCAP prosthesis (control), followed by another 6 weeks of the same exercises with the BALCAP prosthesis (intervention). Tests were performed before and after each 6 week period. Exercises included: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, with turns and movements other than straight forward walking, eyes open.
The invention relates to pharmaceutical compositions for treating or preventing infection by influenza. The disclosure provides treatments comprising immune cells, such as natural killer cells, and antibodies or vaccines that target influenza. Compositions and kit-of-parts comprising said immune cells and antibodies or vaccines are also provided. The disclosure also provides engineered immune cells expressing a chimeric antigen receptor (CAR). Such CAR expressing cells are useful for treatment. Exemplary influenza targets of the present invention include the influenza viral hemagglutinin (HA) protein, the extracellular domain of an influenza viral M2 protein (M2e), and the influenza viral neuraminidase (NA) protein, in particular evolutionary conserved epitopes thereof.
Solid therapeutic compsn. comprises aspirin and/or its derivs. with dipyridamole, each active component being sepd. from the other by the excipient. The compsn. inhibits aggregation of blood platelets. A typical 3-layer table contained a nucleus of 150 mg of dipyridamole with excipient, an inactive isolating layer of lactose and starch, and an outer layer of 150 mg of aspirin with excipient.
The present disclosure provides activatable and detectable membrane-interacting peptides that, following activation, can interact with phospholipid bilayers, such as cell membranes. The present disclosure also provides methods of use of such compounds. The compounds of the present disclosure are of the general structure X la -A-X 2 -Z-X lb , where A is a membrane-interacting peptide region having a plurality of nonpolar hydrophobic amino acid residues that, following separation from portions Z, is capable of interaction with a phospholipid bilayer; Z is an inhibitory peptide region that can inhibit the activity of portion A; X 2  is a cleavable linker that can be cleaved to release cleavage products from the compound; and X la  and X lb  are optionally-present chemical handles that facilitate conjugation of various cargo moieties to the compound. Prior to cleavage of the composition at X 2 , the composition acts as a promolecule that does not associate with cellular membranes to a significant or detectable level. Following cleavage at cleavable linker X 2 , the cleavage product including portion A is free to interact with a phospholipid bilayer (e.g., a cell membrane), and thus accumulate at a site associated with a cleavage-promoting environment. Detection of the membrane-associated cleavage product can be accomplished by detection of a moiety attached through X la  and/or X lb . Such compositions can be used in a variety of methods, including, for example, use in directly imaging active clotting within a subject.
FIELD: pharmaceutics. SUBSTANCE: the present innovation deals with aqueous pharmaceutical compositions of erythropoietin being free of human serum products, stabilized with amino acid and derivatives of sorbitan mono-9-octadecenoate poly(oxy- 1.2-ethandiyl). The present innovation, also, deals with aqueous stable pharmaceutical erythropoietin compositions containing conservants that contain antibacterial quantities of cresol and amino acid. Pharmaceutical compositions are stable and free of human blood products, such as albumin. EFFECT: higher efficiency. 52 cl, 4 dwg, 7 tbl
Large biobank samples provide an opportunity to integrate broad phenotyping, familial records, and molecular genetics data to study complex traits and diseases. We introduce Pearson-Aitken Family Genetic Risk Scores (PA-FGRS), a method for estimating disease liability from patterns of diagnoses in extended, age-censored genealogical records. We then apply the method to study a paradigmatic complex disorder, major depressive disorder (MDD), using the iPSYCH2015 case-cohort study of 30,949 MDD cases, 39,655 random population controls, and more than 2 million relatives. We show that combining PA-FGRS liabilities estimated from family records with molecular genotypes of probands improves three lines of inquiry. Incorporating PA-FGRS liabilities improves classification of MDD over and above polygenic scores, identifies robust genetic contributions to clinical heterogeneity in MDD associated with comorbidity, recurrence, and severity and can improve the power of genome-wide association studies. Our method is flexible and easy to use, and our study approaches are generalizable to other datasets and other complex traits and diseases.
Ventilatory suppression in children following opioid administration is of obvious concern, especially following routine surgical procedures (i.e. adenotonsillectomy). It is thought that patients with obstructive sleep apnea (OSA) have increased sensitivity to opioids, and especially in opioid naïve patients. Recent evidence in adults suggests that patients with moderate to severe OSA may not predispose patients to increased opioid sensitivity in the form of respiratory depression when compared with patients that do not have OSA. It is well known that OSA in children is significantly different from OSA in adults (e.g. gender predilection, central vs. peripheral causation). The manifestation and etiologies are very different in pediatric OSA making it a vastly different disease process.
PURPOSE: To protect leukocytes in dissolving erythrocytes, by treating a blood sample pretreated with an anticoagulant with a preparation for protecting leukocytes containing a reagent for fixing leukocytes before hypotonic lysing erythrocytes so as to accurately analyze leukocytes. CONSTITUTION: In this method for protecting leukocytes, a blood sample pretreated with an anticoagulant is treated with a preparation for protecting leukocytes containing a reagent for fixing leukocytes, containing an aliphatic aldehyde (e.g. formaldehyde), an alkali metal or alkaline earth metal salt (e.g. magnesium acetate), optionally an agent (e.g. saccharose) to adjust isotonicity, etc., before hypotonic lysing erythrocytes so that leukocytes are protected so as to accurately analyze leukocytes. The blood sample of protected leukocytes is subjected to cytophotometry analysis after hypotonic lysing erythrocytes to accurately analyze a leukocyte group of blood sample.
An apparatus for providing information about a user's brain resources is provided. The apparatus includes at least sensor interface circuitry and processing circuitry coupled to the sensor interface circuitry. In a calibration mode, the sensor interface circuitry is configured to receive first sensor data from an electroencephalography sensor. The first sensor data are indicative of an electroencephalogram of the user. Further, the sensor interface circuitry is configured to receive second sensor data from a physiological sensor in the calibration mode. The second sensor data are indicative of a physiological property of the user. In the calibration mode, the processing circuitry is configured to train a brain-physiological model for the user based on the first sensor data and the second sensor data.
A method of obtaining Factor VIII which comprises (a) adding heparin to freshly obtained blood plasma collected into a calcium chelating anticoagulant or collecting blood plasma by plasma pheresis using heparin and a calcium chelating anticoagulant; (b) freezing the plasma; (c) resolubilizing the plasma; (d) isolating a cryoprecipitate from the plasma; (e) resolubilizing the cryoprecipiate; (f) adding a citrate saline heparin buffer to the resolubilized cryoprecipitate; (g) incubating the buffered, resolubilized cryoprecipitate at a temperature of from about 0 DEG to about 10 DEG  C. for a time in excess of about one hour, whereby Factor VIII present in the cryoprecipitate is insolubilized using heparin precipitable cold insoluble globulin and the resulting Factor VIII rich precipitate also includes cold insoluble globulin; (h) separating the Factor VIII rich precipitate; and (i) isolating Factor VIII therefrom. The introduction of the cold insoluble globulin (CIg) step to Factor VIII production results in markedly increased yields of Factor VIII in the cryoprecipitate and, as well, in the cold-insoluble globulin obtained from the cryoprecipitate. Using this procedure, 81% of the Factor VIII is recovered in the cryoprecipitate. The cold-insoluble globulin contains 62% of the starting Factor VIII activity. A final recovery of 666 units per liter of starting plasma is therefore obtained and the amount of protein is reduced to less than 1%. In addition, the procedure can be carried out in blood donor centers, although it is also envisaged to be useful in larger scale recovery of Factor VIII procedures.
Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 200 mg itraconazole on Days 10 to 18.
This is a multicenter, randomized, double-blind controlled clinical trial. The trial has been designed to determine whether total homocysteine lowering treatment with a standard multivitamin augmented by a multivitamin containing no folic acid B12, and vitamin B6, versus treatment with an identical multivitamin containing no folic acid, will reduce the pooled rate of recurrent or new cardiovascular disease outcomes or events. Participants will have a brief visit, at which the participant will have physical measurements, blood pressure and history taken. Urine and blood tests will be performed to determine the levels of homocysteine, vitamins and creatinine. Qualifying participants will be randomly assigned to receive multivitamins containing a high dose of folic acid, vitamin B6, and vitamin B12, or an identical multivitamin containing no folic acid, and estimated average requirement amounts of vitamin B6 and vitamin B12. The participant will be required to return annually throughout the next five years for physical exams, blood and urine tests.
FIELD: stomatology. SUBSTANCE: invention, in particular, relates to treatment of dental roots. Active principle of composition is effective amount of ethylenediaminetetraacetic acid: at least 80-90 wt % of its saturation concentration in aqueous matrix. Treatment consists in that parts of open surface of root are selectively removed in order to improve subsequent attachment of tooth to root membrane after surgical intervention. EFFECT: strengthened attachment of tooth. 25 cl, 2 ex
It will consist of the group of patients who will use copaiba mouthwash. It will be subdivided into 6 consecutive cohorts.
After the closure of the aponeurosis, and before the closure of the skin, the subcutaneous layer of the wound will be rinsed with a determined volume (depending on the diameter of the incision) of amoxicillin-clavulanate in saline solution. Then, a gauze soaked with the same solution will be placed in the wound for 3 minutes.
Healthy Japanese participants, randomized in the ratio 3:1 in each of the cohorts will receive single ascending dose of either NNC0491-6075 or placebo in 3 cohorts (Cohort C1,C2 and C3). The route of administration will be subcutaneous or intravenous.
Patients will be randomize in other Group 1, where these parameters (from the device Respiratory Function Monitor) of lung mechanics would be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). We adapt or change PIP using visible TVe.
Although direct pharmacological effects of antidepressant should manifest rapidly, before significant symptom relief appears, typically antidepressant treatment needs to be continued for 2 to 4 weeks. This delayed onset of clinical effects indicates involvement of adaptive changes in antidepressant effects. Rodent studies have consistently shown upregulation of the 3, 5-cyclic adenosine monophosphate (cAMP) system induced by different types of chronic but not acute antidepressant treatment including serotonin and norepinephrine uptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, lithium and electroconvulsions. cAMP is synthesized from adenosine 5-triphosphate (ATP) by adenylyl cyclase and metabolized by cyclic nucleotide phosphodiesterases (PDEs). Type 4 PDE (PDE4) is selective to cAMP in the brain. Among components of the cAMP pathway, PDE4 appears to be critical for antidepressant effects because an inhibitor of PDE4, 4-\[3-(cyclopenotoxyl)-4-methoxyphenyl\]-2-pyrrolidone (rolipram), showed antidepressant effects both in animals and humans, and various forms of antidepressant treatment induced increase in PDE4 in rodents. However, without imaging the cAMP pathway before and after antidepressant treatment in depressives, it is not possible to study adaptive changes in the signal transduction system and its role in the symptom relief.

Recently (R)-\[(11)C\]rolipram has been successfully used to image PDE4 in animals and humans. We have confirmed that PDE4 levels can be measured reliably by performing (R)-\[(11)C\]rolipram positron emission tomography (PET) with multiple arterial sampling even in rats. The primary purpose of this protocol is to compare PDE4 levels before and after starting a selective serotonin reuptake inhibitor (SSRI) sertraline, citalopram or escitalopram in unmedicated depressed patients. The secondary purpose is to compare PDE4 levels between unmedicated depressed patients and healthy subjects. Baseline scans of patients will be used for this second comparison. For the first time, these comparisons have become possible with the new PET agent (R)-\[(11)C\]rolipram. The findings will advance understanding on the role of cAMP signal transduction system in the pathology of depression and the mechanisms of antidepressant effects.
The caregiver assistance system helps the caregiver manage the care of the patient and the bed that supports the patient. The system monitors tasks associated with the patient, such as caregiver patrol tasks, decubitus ulcer assessment, and/or fall risk assessment, and forwards completed tasks to the EMR server. The system also monitors the state of the bed and determines compliance with one or more medical facility protocols. Over time, the system collects data from multiple beds regarding how frequently the beds comply with medical facility agreements and generates compliance level reports that help managers manage their medical facilities. The system may also monitor how quickly the caregiver responds to one or more alarm conditions associated with the bed and/or patient and generate reports for the administrator regarding response times. In some embodiments, the system may also provide operating guidelines to the caregiver that operate the features of the bed and/or comply with medical facility protocols.
BACKGROUND Adenocarcinomas and pancreatic neuroendocrine tumors (pNETs) display some similarities and differences. The aim of this study was to compare preoperative data and morphological parameters, and to assess postoperative complications after resection. MATERIAL AND METHODS Data of 162 patients who underwent distal pancreatic resection for neuroendocrine or adenocarcinoma tumor were retrospectively analyzed. After applying inclusion and exclusion criteria, 131 patients were included in the study. The preoperative data analyzed included age, sex, and ASA-PS (American Society of Anesthesiologists Physical Status) grade. The diameter of the pancreatic duct and the texture of the pancreas were analyzed. Postoperative data included grading (G1-G3), the presence of PanIN (pancreatic intraepithelial neoplasia), infiltration of structures, and postoperative complications. RESULTS Patients with adenocarcinoma were statistically older and had a higher ASA-PS class than patients with NET (P<0.001). Statistically significantly more patients with adenocarcinoma had a histopathological diagnosis of G3 (p<0.001). In patients with adenocarcinomas infiltration of structures occurred more frequently. Pancreatic duct diameter ≥3 mm was more common in patients with adenocarcinoma (P=0.045). Clinically significant pancreatic fistulas were more frequent in patients with neuroendocrine tumors (P=0.044). CONCLUSIONS Adenocarcinomas in the pancreatic body and tail are more aggressive, they cause more frequent infiltration of structures, and more often metastasize to lymph nodes compared to NETs. NETs tend to have softer pancreatic texture and higher incidence of clinically significant pancreatic fistulas, but postoperative complications of Clavien-Dindo grade ≥III occur at a similar rate in both groups.
Hypertension is the key contributor to pathological cardiac hypertrophy. Growing evidence indicates that glucose metabolism plays an essential role in cardiac hypertrophy. TP53-induced glycolysis and apoptosis regulator (TIGAR) has been shown to regulate glucose metabolism in pressure overload-induced cardiac remodeling. In the present study, we investigated the role of TIGAR in cardiac remodeling during Angiotensin II (Ang-II)-induced hypertension. Wild-type (WT) and TIGAR knockout (KO) mice were infused with Angiotensin-II (Ang-II, 1 µg/kg/min) via mini-pump for four weeks. The blood pressure was similar between the WT and TIGAR KO mice. The Ang-II infusion resulted in a similar reduction of systolic function in both groups, as evidenced by the comparable decrease in LV ejection fraction and fractional shortening. The Ang-II infusion also increased the isovolumic relaxation time and myocardial performance index to the same extent in WT and TIGAR KO mice, suggesting the development of similar diastolic dysfunction. However, the knockout of TIGAR significantly attenuated hypertension-induced cardiac hypertrophy. This was associated with higher levels of fructose 2,6-bisphosphate, PFK-1, and Glut-4 in the TIGAR KO mice. Our present study suggests that TIGAR is involved in the control of glucose metabolism and glucose transporters by Ang-II and that knockout of TIGAR attenuates the development of maladaptive cardiac hypertrophy.
PURPOSE: A transdermal delivery of agents, is provided which is such as peptides and proteins, through the skin of an animal, as well as the transdermal sampling of agents, such as glucose, electrolyte and substances of abuse, such as but not limited to alcohol and illicit drugs. CONSTITUTION: A high volume is producable, low-cost device suitable for increasing transdermal flux with skin piercing protrusions and contacting a body surface over a large contact area to reduce skin irritation and enhance agent delivery or sampling. The device of the present invention pierces the stratum corneum of a body surface to form pathways through which a substance can either be introduced (i.e., delivery) or withdrawn (i.e., sampling). In one aspect, the invention comprises a plurality of protrusions for piercing the skin which extend through a connecting medium. The connecting medium assists in making substantial contact with the body surface for either delivering or sampling an agent. For an electrotransport device, the connecting medium spreads out the contact area to all the protrusions to reduce the current density at particular locations to reduce irritation.
WalkMORE is a single-center randomized controlled trial. The investigators will enroll up to 300 ambulatory patients admitted to the Internal Medicine unit (located on the 4th floor of University Hospital) who are \>18 years of age and are anticipated to require a \>48 hour hospital admission. A maximum of 6 patients will be assigned to each treatment arm at any given time. The investigators will recruit patients into the WalkMORE program over a 3-month period. The research coordinator (RC) will screen patients admitted to the Internal Medicine unit in the preceding 24-hour period to identify patients who fulfill the eligibility criteria. Patients will be randomized via REDCap (Research Electronic Data Capture), a secure, centralized web-based randomization module to:

1. Standard of care; or
2. WalkMORE Ambulation program + Standard of care. Patients will ambulate with a trained WalkMORE Volunteer Coach two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge. Patients randomized to the WalkMORE intervention will be assessed daily by the RC to ensure patients remain fit for independent ambulation. The duration of each walking session will be determined daily by the RC and the medical team.

After obtaining written informed consent from eligible patients the RC will randomize patients, collect demographics, hospital admission details and perform a quality of life survey (EQ-5D) with all patients. All patients will be assigned a scientific pedometer on the day of randomization. The modus Health StepWatch™ is an activity monitor worn on the ankle via a velcro strap. It is a small, lightweight device that will count and record patients' steps throughout their hospital stay. The device is smaller than a deck of cards (7.5 x 5.0 x 2.0 cm) and weighs 38 grams and will be installed by the RC. The total number of steps recorded on the pedometer will be collected for each patient every day until hospital discharge. For patients randomized to the WalkMORE intervention arm, the total number of minutes walked with a volunteer coach will also be recorded for each session until discharge. Functional ability will be measured on the third day post-randomization and every three days thereafter until hospital discharge, using the Timed Up and Go test (patients will be asked to stand up from a chair, walk three metres, turn around, walk back to the chair, and sit). After hospital discharge the RC will follow up with patients for 2 brief telephone interviews. On day 3 after discharge, Patient Satisfaction surveys will be conducted by the RC to assess patient satisfaction with their experience with the WalkMORE program. These telephone surveys will be reviewed and approved by Lisa Hawthorne of the Patient Experience Office. On day 30 after discharge the RC will contact patients to conduct a brief quality of life survey and to collect data regarding clinical outcomes (ER visits, re-hospitalizations, and falls). Each telephone interview is expected to last approximately 10-15 minutes.